Merkel cell carcinoma: What makes a difference?

Jennifer Tseng, Birat Dhungel, Jane K. Mills, Brian S. Diggs, Roshanthi Weerasinghe, Jeanine Fortino, John Vetto

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Background Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine tumor that may spread via lymphatics and can therefore be staged with sentinel lymph node biopsy (SLNB). MCC is radiosensitive and chemosensitive, although the role of adjuvant therapy is still unclear. We examined the impact of different treatments on the outcome of MCC. Methods We performed a retrospective review of state cancer registry data from California, Oregon, and Washington of patients diagnosed with primary skin MCC between 1988 and 2012 (n = 4,038). Data were analyzed using Cox regression and Kaplan-Meier methods to examine disease-specific survival. Results Patients with positive nodes or no documented nodal evaluation had worse survival compared with node-negative patients. No nodal evaluation had decreased survival compared with lymph node evaluation by SLNB. Completion lymph node dissection conferred improved survival in patients with a positive SLNB. In clinically node-negative patients who had a positive SLNB, radiation and chemotherapy did not affect survival. Conclusions Lymph node evaluation is an important component to MCC treatment. The role of adjuvant radiation and chemotherapy needs further evaluation.

    Original languageEnglish (US)
    Pages (from-to)342-346
    Number of pages5
    JournalAmerican Journal of Surgery
    Volume209
    Issue number2
    DOIs
    StatePublished - Feb 1 2015

    Fingerprint

    Merkel Cell Carcinoma
    Sentinel Lymph Node Biopsy
    Survival
    Lymph Nodes
    Radiation
    Skin
    Neuroendocrine Tumors
    Adjuvant Chemotherapy
    Lymph Node Excision
    Registries
    Drug Therapy
    Therapeutics
    Neoplasms

    Keywords

    • Chemotherapy
    • Keywords Merkel cell carcinoma
    • Lymph node
    • Radiation

    ASJC Scopus subject areas

    • Surgery
    • Medicine(all)

    Cite this

    Tseng, J., Dhungel, B., Mills, J. K., Diggs, B. S., Weerasinghe, R., Fortino, J., & Vetto, J. (2015). Merkel cell carcinoma: What makes a difference? American Journal of Surgery, 209(2), 342-346. https://doi.org/10.1016/j.amjsurg.2014.06.013

    Merkel cell carcinoma : What makes a difference? / Tseng, Jennifer; Dhungel, Birat; Mills, Jane K.; Diggs, Brian S.; Weerasinghe, Roshanthi; Fortino, Jeanine; Vetto, John.

    In: American Journal of Surgery, Vol. 209, No. 2, 01.02.2015, p. 342-346.

    Research output: Contribution to journalArticle

    Tseng, J, Dhungel, B, Mills, JK, Diggs, BS, Weerasinghe, R, Fortino, J & Vetto, J 2015, 'Merkel cell carcinoma: What makes a difference?', American Journal of Surgery, vol. 209, no. 2, pp. 342-346. https://doi.org/10.1016/j.amjsurg.2014.06.013
    Tseng J, Dhungel B, Mills JK, Diggs BS, Weerasinghe R, Fortino J et al. Merkel cell carcinoma: What makes a difference? American Journal of Surgery. 2015 Feb 1;209(2):342-346. https://doi.org/10.1016/j.amjsurg.2014.06.013
    Tseng, Jennifer ; Dhungel, Birat ; Mills, Jane K. ; Diggs, Brian S. ; Weerasinghe, Roshanthi ; Fortino, Jeanine ; Vetto, John. / Merkel cell carcinoma : What makes a difference?. In: American Journal of Surgery. 2015 ; Vol. 209, No. 2. pp. 342-346.
    @article{fa78b006d106490c863f37af97024a1d,
    title = "Merkel cell carcinoma: What makes a difference?",
    abstract = "Background Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine tumor that may spread via lymphatics and can therefore be staged with sentinel lymph node biopsy (SLNB). MCC is radiosensitive and chemosensitive, although the role of adjuvant therapy is still unclear. We examined the impact of different treatments on the outcome of MCC. Methods We performed a retrospective review of state cancer registry data from California, Oregon, and Washington of patients diagnosed with primary skin MCC between 1988 and 2012 (n = 4,038). Data were analyzed using Cox regression and Kaplan-Meier methods to examine disease-specific survival. Results Patients with positive nodes or no documented nodal evaluation had worse survival compared with node-negative patients. No nodal evaluation had decreased survival compared with lymph node evaluation by SLNB. Completion lymph node dissection conferred improved survival in patients with a positive SLNB. In clinically node-negative patients who had a positive SLNB, radiation and chemotherapy did not affect survival. Conclusions Lymph node evaluation is an important component to MCC treatment. The role of adjuvant radiation and chemotherapy needs further evaluation.",
    keywords = "Chemotherapy, Keywords Merkel cell carcinoma, Lymph node, Radiation",
    author = "Jennifer Tseng and Birat Dhungel and Mills, {Jane K.} and Diggs, {Brian S.} and Roshanthi Weerasinghe and Jeanine Fortino and John Vetto",
    year = "2015",
    month = "2",
    day = "1",
    doi = "10.1016/j.amjsurg.2014.06.013",
    language = "English (US)",
    volume = "209",
    pages = "342--346",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Merkel cell carcinoma

    T2 - What makes a difference?

    AU - Tseng, Jennifer

    AU - Dhungel, Birat

    AU - Mills, Jane K.

    AU - Diggs, Brian S.

    AU - Weerasinghe, Roshanthi

    AU - Fortino, Jeanine

    AU - Vetto, John

    PY - 2015/2/1

    Y1 - 2015/2/1

    N2 - Background Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine tumor that may spread via lymphatics and can therefore be staged with sentinel lymph node biopsy (SLNB). MCC is radiosensitive and chemosensitive, although the role of adjuvant therapy is still unclear. We examined the impact of different treatments on the outcome of MCC. Methods We performed a retrospective review of state cancer registry data from California, Oregon, and Washington of patients diagnosed with primary skin MCC between 1988 and 2012 (n = 4,038). Data were analyzed using Cox regression and Kaplan-Meier methods to examine disease-specific survival. Results Patients with positive nodes or no documented nodal evaluation had worse survival compared with node-negative patients. No nodal evaluation had decreased survival compared with lymph node evaluation by SLNB. Completion lymph node dissection conferred improved survival in patients with a positive SLNB. In clinically node-negative patients who had a positive SLNB, radiation and chemotherapy did not affect survival. Conclusions Lymph node evaluation is an important component to MCC treatment. The role of adjuvant radiation and chemotherapy needs further evaluation.

    AB - Background Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine tumor that may spread via lymphatics and can therefore be staged with sentinel lymph node biopsy (SLNB). MCC is radiosensitive and chemosensitive, although the role of adjuvant therapy is still unclear. We examined the impact of different treatments on the outcome of MCC. Methods We performed a retrospective review of state cancer registry data from California, Oregon, and Washington of patients diagnosed with primary skin MCC between 1988 and 2012 (n = 4,038). Data were analyzed using Cox regression and Kaplan-Meier methods to examine disease-specific survival. Results Patients with positive nodes or no documented nodal evaluation had worse survival compared with node-negative patients. No nodal evaluation had decreased survival compared with lymph node evaluation by SLNB. Completion lymph node dissection conferred improved survival in patients with a positive SLNB. In clinically node-negative patients who had a positive SLNB, radiation and chemotherapy did not affect survival. Conclusions Lymph node evaluation is an important component to MCC treatment. The role of adjuvant radiation and chemotherapy needs further evaluation.

    KW - Chemotherapy

    KW - Keywords Merkel cell carcinoma

    KW - Lymph node

    KW - Radiation

    UR - http://www.scopus.com/inward/record.url?scp=84922596642&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84922596642&partnerID=8YFLogxK

    U2 - 10.1016/j.amjsurg.2014.06.013

    DO - 10.1016/j.amjsurg.2014.06.013

    M3 - Article

    C2 - 25152250

    AN - SCOPUS:84922596642

    VL - 209

    SP - 342

    EP - 346

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 2

    ER -